CCM
SAGE

Cinctive Capital Management’s Sage Therapeutics SAGE Stock Holding History

Cinctive Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-39,979
Closed -$1.32M – 623
2022
Q1 		$1.32M Sell
39,979
-17,200
-30% -$647K 0.05% 375
2021
Q4 		$2.43M Buy
57,179
+17,779
+45% +$744K 0.11% 274
2021
Q3 		$1.75M Buy
+39,400
New +$1.81M 0.09% 324

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cinctive Capital Management's SAGE Position: Q2 2022 in Review

Cinctive Capital Management sold out of Sage Therapeutics (SAGE) in Q2 2022, closing a stake of 39,979 shares — an estimated $1.32M sold.

Cinctive Capital Management first reported a position in SAGE in Q3 2021 and held it in 3 quarters. The position peaked at $2.43M in Q4 2021. 209 funds tracked by Wall St. Rank hold SAGE as of Q2 2022.

  • Cinctive Capital Management reported no remaining Sage Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Cinctive Capital Management sold 39,979 Sage Therapeutics shares in Q2 2022, an estimated $1.32M.
  • Cinctive Capital Management first reported a position in Sage Therapeutics in Q3 2021 and held it in 3 quarters.
  • Cinctive Capital Management's Sage Therapeutics position peaked at $2.43M in Q4 2021.
  • 209 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2022.

Based on Cinctive Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.